Premium
ALG11‐CDG syndrome: Expanding the phenotype
Author(s) -
Haanpää Maria K.,
Ng Bobby G.,
Gallant Natalie M.,
Singh Kathryn E.,
Brown Candida,
Kimonis Virginia,
Freeze Hudson H.,
Muller Eric A.
Publication year - 2019
Publication title -
american journal of medical genetics part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.064
H-Index - 112
eISSN - 1552-4833
pISSN - 1552-4825
DOI - 10.1002/ajmg.a.61046
Subject(s) - glycosylation , phenotype , glycan , transferrin , clinical phenotype , biomarker , compound heterozygosity , glycoprotein , psychomotor retardation , medicine , bioinformatics , biology , genetics , gene , endocrinology , pathology , alternative medicine
ALG11‐Congenital Disorder of Glycosylation (ALG11‐CDG, also known as congenital disorder of glycosylation type Ip) is an inherited inborn error of metabolism due to abnormal protein and lipid glycosylation. We describe two unrelated patients with ALG11‐CDG due to novel mutations, review the literature of previously described affected individuals, and further expand the clinical phenotype. Both affected individuals reported here had severe psychomotor disabilities and epilepsy. Their fibroblasts synthesized truncated precursor glycan structures, consistent with ALG11‐CDG, while also showing hypoglycosylation of a novel biomarker, GP130. Surprisingly, one patient presented with normal transferrin glycosylation profile, a feature that has not been reported previously in patients with ALG11‐CDG. Together, our data expand the clinical and mutational spectrum of ALG11‐CDG.